Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback